![]() Sernova | Stem Cell for Diabetes Treatment ![]() Paul Laikind, ViaCyte’s President and CEO, “For more than a decade, BetaLogics and ViaCyte have been independently working toward a stem cell-derived therapy for diabetes. By combining the intellectual property and other assets of BetaLogics with ViaCyte, we will further strengthen our advanced program focused on insulin-dependent diabetes and solidify our leadership in the field.”Īccording to ViaCyte, it differentiates stem cells into pancreatic beta cell precursors (PEC-01™) and subcutaneously implants them into patients using a retrievable medical device (an Encaptra® cell delivery system), allowing the implanted precursor cells to mature into endocrine cells that can secrete insulin and other hormones in a controlled manner to support healthy blood glucose levels.Ĥ. #Stem cell treatment for diabetes type 2 cost license#In February 2016, San Diego-based ViaCyte acquired an exclusive license to “BetaLogics intellectual property in the field of metabolic disease, including diabetes, and the transfer of related assets to ViaCyte.” The news positioned ViaCyte as a leader in stem cell therapeutics for the treatment of Types 1 and 2 diabetes.Īccording to Dr. Given the growing promise of regenerative medicine, the following companies are exploring the use of stem cells for diabetes. Other innovative approaches to the treatment of diabetes are explored below. In a historic achievement, the Diabetes Research Institute a Center of Excellence at the University of Miami Miller School of Medicine announced the first diabetic patient in its clinical trial had stopped insulin therapy after the implantation of islet cells within a biological scaffold. was “$245 billion per annum or approximately $500,000 every minute.”įortunately, companies and institutions worldwide are making progress with stem cell for diabetes treatment. ![]() According to the American Diabetes Association, the 2012 cost of this disease in the U.S. ![]() population has diabetes, including an estimated 8.1 million who are undiagnosed. With an aging population, surging rates of obesity, and the incidence of diabetes on the rise, these companies are exploring the use of stem cells and cell therapies for diabetes treatment.Īccording to the Center for Disease Control (CDC), 29.1 million people or 9.3% of the U.S. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |